

Product sheet

NCI-H2195 | 305259

General Information

**Description** NCI-H2195 is a human small cell lung carcinoma (SCLC) cell line. It is derived from a 67-year-old male patient with a primary tumor in the right lung. The cell line is characterized by its high growth rate and its ability to form neuroendocrine tumors. It is commonly used in research to study the biology of SCLC and to test new therapies.

**Organism** Human

**Tissue** Lung

**Disease** Small cell lung carcinoma

**Metastatic site** Liver

**Synonyms** H2195, H-2195

Cell Culture

**Age** 67 years

**Gender** Male

**Ethnicity** Caucasian

**Growth properties** Adherent

Identification

**Citation** NCI-H2195 (ATCC CCL-221) | Cytion 305259

**Biosafety level** 1

**NCBI\_TaxID** 9606

**CellosaurusAccession** CVCL\_1538

Additional Information

Product sheet

NCI-H2195 | 305259

**Mutational profile** TP53, p.Val157Phe (c.469G>T)

**Culture Medium** DMEM:Ham's F12 (1:1), w: 3.1 g/L , w: 1.6 mM L-, w: 15 mM HEPES, w: 1.0 mM , w: 1.2 g/L NaHCO3 820400a)

**Supplements** 10% FBS, ITS+, 10 nM, β- 10 nM, L-

**Dissociation Reagent**

**Subculturing** 10% FBS, ITS+, 10 nM, β- 10 nM, L- 10% FBS, ITS+, 10 nM, β- 10 nM, L- 10% FBS, ITS+, 10 nM, β- 10 nM, L-

**Split ratio** 1:2 1:3

**Fluid renewal**

**Freeze medium** 10% FBS + 10% DMSO

Thawing and Culturing Cells

1. 10% FBS, ITS+, 10 nM, β- 10 nM, L- 10% FBS, ITS+, 10 nM, β- 10 nM, L-
2. 10% FBS, ITS+, 10 nM, β- 10 nM, L- 10% FBS, ITS+, 10 nM, β- 10 nM, L-
3. 10% FBS, ITS+, 10 nM, β- 10 nM, L- 10% FBS, ITS+, 10 nM, β- 10 nM, L-
4. 10% FBS, ITS+, 10 nM, β- 10 nM, L- 10% FBS, ITS+, 10 nM, β- 10 nM, L-
5. 10% FBS, ITS+, 10 nM, β- 10 nM, L- 10% FBS, ITS+, 10 nM, β- 10 nM, L-
6. 10% FBS, ITS+, 10 nM, β- 10 nM, L- 10% FBS, ITS+, 10 nM, β- 10 nM, L-
7. 10% FBS, ITS+, 10 nM, β- 10 nM, L- 10% FBS, ITS+, 10 nM, β- 10 nM, L-
8. 10% FBS, ITS+, 10 nM, β- 10 nM, L- 10% FBS, ITS+, 10 nM, β- 10 nM, L-

